Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anti-herpes treatment found to reduce genital and plasma HIV levels in women infected with both HIV and herpes viruses

22.02.2007
Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published Treating women who are infected with both the HSV-2 and HIV viruses with anti-herpes treatment can reduce the amount of HIV in the blood and genital secretions, according to the results of a trial published today in the New England Journal of Medicine.

A collaborative group of scientists from the Centre Muraz (Burkina Faso), the University of Montpellier (France) and the London School of Hygiene & Tropical Medicine (UK) carried out the trial among women co-infected with the human immuno-deficiency virus (HIV) and the virus that causes genital herpes (HSV-2) in Burkina Faso. The results showed that having the herpes virus increased the replication of HIV, and also revealed that the quantity of HIV in the blood and in the vagina was reduced by continuous anti-herpes treatment over 3 months.

These findings open new avenues for the prevention of HIV transmission and for the management of patients co-infected by the two viruses.

In 2005, an estimated 4.1 million people were newly infected with HIV, mostly through heterosexual intercourse1. This alarming number of infections highlights the urgent need to intensify and expand proven prevention methods, and further, to identify and implement new methods of HIV prevention.

... more about:
»Genital »HIV »HSV »HSV-2 »Herpes »Vaccine

A number of observational studies have indicated that HSV-2 enhances the risk of HIV-1 acquisition by around three-fold2. HSV-2 infection may also increase HIV-1 infectiousness by disrupting the genital mucosa and increasing the levels of HIV in the genital tract3, allowing easier transmissibility of the virus. In addition, the HIV viral load in the blood of HIV-1 infected patients increases, at least temporarily, during episodes of HSV reactivation.

Lead author Dr. Nicolas Nagot, of the London School of Hygiene & Tropical Medicine (LSHTM), explains: ‘Behavioural interventions are not always successful, as knowledge does not necessarily translate into sexual behaviour change. Therefore, innovative methods that target the biological susceptibility of individuals to acquire or transmit HIV are also required. A number of options to prevent HIV transmission are currently being investigated, including the role of vaginal microbicides, pre-exposure HIV prophylaxis, male circumcision, and - in the future - an HIV vaccine.’

‘The results of the trial are striking’, he adds. ‘They show that valacyclovir significantly reduces the frequency and quantity of HIV detectable in genital secretions and, in addition, reduces the quantity of HIV in the plasma. As expected, there was also dramatic reduction in the detection of symptomatic and asymptomatic presence of HSV-2. The effects appeared to gradually increase over the 3 month follow-up period, with no sign of abating.’

These results indicate a new way to possibly reduce the sexual transmission of HIV from already infected individuals to their partners, since the frequency and quantity of HIV in the female genital tract are closely related to the transmission of the virus.

The findings will need to be confirmed by further research, and there is already a large ongoing trial that is measuring direct transmission of HIV between discordant couples in several sites worldwide.

Dr Philippe Mayaud, one of Dr Nagot’s colleagues at the LSHTM concludes: ‘Our results have important potential implications for public health and clinical practice, as HSV-2 control could become a new form of HIV prevention targeting HIV-infected individuals, as well as providing clinical benefits. Importantly, an HSV vaccine that would either prevent HSV infection or diminish the clinical and sub-clinical manifestations of HSV with a similar efficacy on HIV as HSV suppressive therapy, would represent a long-lasting form of HIV prevention. The development and evaluation of an HSV vaccine should rank high on the international research agenda.’

Gareth Thomas, UK Minister for International Development, whose department DFID has provided supplementary funding for the research, said: "These exciting initial findings demonstrate why research into reducing HIV/ AIDS transmission is such a vital element of the fight against the disease. The UK Government has pledged to spend £1.5 billion tackling HIV/AIDS in developing countries between 2005 and 2008. We will follow the next stages of this research with interest."

Philippe Mayaud | alfa
Further information:
http://www.lshtm.ac.uk

Further reports about: Genital HIV HSV HSV-2 Herpes Vaccine

More articles from Life Sciences:

nachricht Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory

nachricht Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>